High expression of genes in the IFN-γ signature was also found to be a prognostic factor in BRAF mutated melanoma patients with resected stage III A–C (AJCC 7th edition) disease regardless of whether they received dabrafenib and trametinib or placebo in the adjuvant setting [30]. The gene discussed is BRAF; the disease is melanoma.